HLA-C and neoplasm: Since the patient who responded to the SV-BR-1-GM regimen with tumor regression (16) carried an MHC class II allele also expressed in SV-BR-1-GM cells, we hypothesize that patients coexpressing SV-BR-1-GM TAAs and expressing matching HLA alleles are more likely to develop a strong tumor-directed immune response than those without such characteristics.